Trial
NCT05789524
The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
ApcinteX Ltd
Collaborators
Centessa Pharmaceuticals plc
Condition
Hemophilia a
Intervention
SerpinPC
Why stopped
Study terminated due to business and strategic decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-03-11